Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft.
Bruton tyrosine kinase inhibitor
acute cellular rejection
case report
chronic lymphocytic leukemia
kidney transplantation
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
06
2024
accepted:
07
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
Identifiants
pubmed: 39267975
doi: 10.3389/fmed.2024.1451264
pmc: PMC11390570
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
1451264Informations de copyright
Copyright © 2024 Stavart, Halfon, Dewarrat, Rotman and Golshayan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
N Engl J Med. 2005 Feb 24;352(8):804-15
pubmed: 15728813
Am J Transplant. 2011 Apr;11(4):867-8
pubmed: 21401863
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Hum Pathol. 1981 May;12(5):432-40
pubmed: 7250955
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Cancer J. 2019 Nov/Dec;25(6):386-393
pubmed: 31764119
N Engl J Med. 2020 Jul 30;383(5):460-473
pubmed: 32726532
Arch Intern Med. 1978 Jul;138(7):1139-40
pubmed: 352296
Am J Transplant. 2021 Feb;21(2):475-483
pubmed: 32976703
Transplantation. 2017 Apr;101(4):704-712
pubmed: 27906827
Transplant Proc. 2018 Oct;50(8):2581-2582
pubmed: 30316403
Clin Transplant. 2018 Aug;32(8):e13338
pubmed: 30074641
Br J Haematol. 2016 Jul;174(1):162-5
pubmed: 26436615
Kidney Int. 1992 Jul;42(1):127-35
pubmed: 1635342
Cancer. 2023 Jul 15;129(14):2192-2200
pubmed: 37016930
Int J Mol Sci. 2019 May 24;20(10):
pubmed: 31137652
Ann Oncol. 2021 Jan;32(1):23-33
pubmed: 33091559
Virchows Arch A Pathol Anat Histol. 1975 Oct 30;368(3):243-51
pubmed: 810955
Am J Transplant. 2008 Nov;8(11):2471-5
pubmed: 18782293
Curr Opin Organ Transplant. 2023 Feb 1;28(1):1-7
pubmed: 36579681
Transplantation. 2013 Aug 15;96(3):e14-5
pubmed: 23917688
Kidney Int. 2021 Feb;99(2):410-420
pubmed: 32818517
Blood Adv. 2022 Jun 14;6(11):3440-3450
pubmed: 35377947
Cancer. 1977 Aug;40(2):855-64
pubmed: 890666
PLoS One. 2015 Mar 26;10(3):e0119156
pubmed: 25811382
Eur J Haematol. 2001 Sep;67(3):158-64
pubmed: 11737248
Cancer. 1987 Aug 15;60(4):827-37
pubmed: 3474054
Transplantation. 2003 Feb 15;75(3):414-6
pubmed: 12589167
Haematologica. 2015 Sep;100(9):1180-8
pubmed: 26088927
Nephrol Dial Transplant. 2009 Dec;24(12):3886-90
pubmed: 19729460
Blood. 2016 Oct 27;128(17):2109
pubmed: 27789434
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
BMJ Case Rep. 2021 Jun 14;14(6):
pubmed: 34127504